Publications by authors named "Mary Saltarelli"

Claim this Profile
H
High throughput bioanalysis of serum 7a-hydroxy-4-cholesten-3-one (C4) using LC-MS/MS: Devising an end-to-end single vial solution for a sample limited application.
Soumya Kandi, Sarah Blink Polakow, John P Savaryn, Kenneth Ruterbories, Mary Saltarelli

J Pharm Biomed Anal· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.
Margreet Kloppenburg, Charles Peterfy, Ida K Haugen, Féline Kroon, Su Chen, Mary Saltarelli

Ann Rheum Dis· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased serum clearance of oligomannose species present on a human IgG1 molecule.
Leslie Alessandri, David Ouellette, Aima Acquah, Mathew Rieser, David Leblond, Mary Saltarelli

MAbs· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Joann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, Jennifer J Bouska, Gail Bukofzer, Mary J Saltarelli

Anticancer Res· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Xuesong Liu, Joann Palma, Robert Kinders, Yan Shi, Cherrie Donawho, Mary Saltarelli

Anal Biochem· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioanalytical method validation for macromolecules in support of pharmacokinetic studies.
JoMarie Smolec, Binodh DeSilva, Wendell Smith, Russell Weiner, Marian Kelly, Mary Saltarelli

Pharm Res· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary type II collagen neoepitope as an outcome measure for relapsing polychondritis.
Virginia B Kraus, Thomas Stabler, Elizabeth T Le, Mary Saltarelli, Nancy B Allen

Arthritis Rheum· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
Paul S Changelian, Mark E Flanagan, Douglas J Ball, Craig R Kent, Kelly S Magnuson, Mary J Saltarelli

Science· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis